Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.

Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bödder J, Schertel JM, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanović S, Löffler MW.

J Immunother Cancer. 2019 Nov 15;7(1):307. doi: 10.1186/s40425-019-0796-5.

PMID:
31730025
2.

Purification and Identification of Naturally Presented MHC Class I and II Ligands.

Nelde A, Kowalewski DJ, Stevanović S.

Methods Mol Biol. 2019;1988:123-136. doi: 10.1007/978-1-4939-9450-2_10.

PMID:
31147937
3.

Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.

Murphy JP, Kim Y, Clements DR, Konda P, Schuster H, Kowalewski DJ, Paulo JA, Cohen AM, Stevanovic S, Gygi SP, Gujar S.

J Proteome Res. 2019 Jun 7;18(6):2666-2675. doi: 10.1021/acs.jproteome.9b00173. Epub 2019 May 29.

PMID:
31095916
4.

Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.

Löffler MW, Mohr C, Bichmann L, Freudenmann LK, Walzer M, Schroeder CM, Trautwein N, Hilke FJ, Zinser RS, Mühlenbruch L, Kowalewski DJ, Schuster H, Sturm M, Matthes J, Riess O, Czemmel S, Nahnsen S, Königsrainer I, Thiel K, Nadalin S, Beckert S, Bösmüller H, Fend F, Velic A, Maček B, Haen SP, Buonaguro L, Kohlbacher O, Stevanović S, Königsrainer A; HEPAVAC Consortium, Rammensee HG.

Genome Med. 2019 Apr 30;11(1):28. doi: 10.1186/s13073-019-0636-8.

5.

Multiplexed Relative Quantitation with Isobaric Tagging Mass Spectrometry Reveals Class I Major Histocompatibility Complex Ligand Dynamics in Response to Doxorubicin.

Murphy JP, Yu Q, Konda P, Paulo JA, Jedrychowski MP, Kowalewski DJ, Schuster H, Kim Y, Clements D, Jain A, Stevanovic S, Gygi SP, Mancias JD, Gujar S.

Anal Chem. 2019 Apr 16;91(8):5106-5115. doi: 10.1021/acs.analchem.8b05616. Epub 2019 Feb 22.

PMID:
30779550
6.

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.

Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS.

Blood. 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830. Epub 2018 Dec 10.

PMID:
30530751
7.

Identification of non-mutated neoantigens presented by TAP-deficient tumors.

Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T.

J Exp Med. 2018 Sep 3;215(9):2325-2337. doi: 10.1084/jem.20180577. Epub 2018 Aug 16.

8.

Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.

Löffler MW, Kowalewski DJ, Backert L, Bernhardt J, Adam P, Schuster H, Dengler F, Backes D, Kopp HG, Beckert S, Wagner S, Königsrainer I, Kohlbacher O, Kanz L, Königsrainer A, Rammensee HG, Stevanović S, Haen SP.

Cancer Res. 2018 Aug 15;78(16):4627-4641. doi: 10.1158/0008-5472.CAN-17-1745. Epub 2018 May 22.

9.

HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Nelde A, Kowalewski DJ, Backert L, Schuster H, Werner JO, Klein R, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S, Walz JS.

Oncoimmunology. 2018 Feb 14;7(4):e1316438. doi: 10.1080/2162402X.2017.1316438. eCollection 2018.

10.

The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.

Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Freudenmann LK, Peper JK, Marcu A, Wang SS, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanović S, Weller M, Eisele G.

Acta Neuropathol. 2018 Jun;135(6):923-938. doi: 10.1007/s00401-018-1836-9. Epub 2018 Mar 20.

PMID:
29557506
11.

Improved Ribo-seq enables identification of cryptic translation events.

Erhard F, Halenius A, Zimmermann C, L'Hernault A, Kowalewski DJ, Weekes MP, Stevanovic S, Zimmer R, Dölken L.

Nat Methods. 2018 May;15(5):363-366. doi: 10.1038/nmeth.4631. Epub 2018 Mar 12.

12.

Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.

Fritsche J, Rakitsch B, Hoffgaard F, Römer M, Schuster H, Kowalewski DJ, Priemer M, Stos-Zweifel V, Hörzer H, Satelli A, Sonntag A, Goldfinger V, Song C, Mahr A, Ott M, Schoor O, Weinschenk T.

Proteomics. 2018 Jun;18(12):e1700284. doi: 10.1002/pmic.201700284. Epub 2018 Apr 10.

13.

CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

Zeiner PS, Zinke J, Kowalewski DJ, Bernatz S, Tichy J, Ronellenfitsch MW, Thorsen F, Berger A, Forster MT, Muller A, Steinbach JP, Beschorner R, Wischhusen J, Kvasnicka HM, Plate KH, Stefanović S, Weide B, Mittelbronn M, Harter PN.

Acta Neuropathol Commun. 2018 Mar 1;6(1):18. doi: 10.1186/s40478-018-0521-5.

14.

Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.

Walz JS, Kowalewski DJ, Backert L, Nelde A, Kohlbacher O, Weide B, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Leuk Lymphoma. 2018 Aug;59(8):1949-1958. doi: 10.1080/10428194.2017.1403022. Epub 2018 Jan 3.

PMID:
29295645
15.

The immunopeptidomic landscape of ovarian carcinomas.

Schuster H, Peper JK, Bösmüller HC, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanović S, Staebler A, Wagner P.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. doi: 10.1073/pnas.1707658114. Epub 2017 Nov 1.

16.

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.

Nelde A, Walz JS, Kowalewski DJ, Schuster H, Wolz OO, Peper JK, Cardona Gloria Y, Langerak AW, Muggen AF, Claus R, Bonzheim I, Fend F, Salih HR, Kanz L, Rammensee HG, Stevanović S, Weber AN.

Oncoimmunology. 2016 Dec 23;6(3):e1219825. doi: 10.1080/2162402X.2016.1219825. eCollection 2017.

17.

MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies.

Murphy JP, Konda P, Kowalewski DJ, Schuster H, Clements D, Kim Y, Cohen AM, Sharif T, Nielsen M, Stevanovic S, Lee PW, Gujar S.

J Proteome Res. 2017 Apr 7;16(4):1806-1816. doi: 10.1021/acs.jproteome.6b00971. Epub 2017 Mar 21.

PMID:
28244318
18.

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz JS.

Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918.

19.

Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.

Barth SM, Schreitmüller CM, Proehl F, Oehl K, Lumpp LM, Kowalewski DJ, Di Marco M, Sturm T, Backert L, Schuster H, Stevanović S, Rammensee HG, Planz O.

PLoS One. 2016 Nov 28;11(11):e0167017. doi: 10.1371/journal.pone.0167017. eCollection 2016.

20.

Erratum to "Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient".

Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG.

J Hepatol. 2017 Jan;66(1):252-253. doi: 10.1016/j.jhep.2016.10.021. Epub 2016 Nov 15. No abstract available.

PMID:
27863814
21.

Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.

Klatt MG, Kowalewski DJ, Schuster H, Di Marco M, Hennenlotter J, Stenzl A, Rammensee HG, Stevanović S.

Oncoimmunology. 2016 Jun 30;5(8):e1204504. doi: 10.1080/2162402X.2016.1204504. eCollection 2016 Aug.

22.

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient.

Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG.

J Hepatol. 2016 Oct;65(4):849-855. doi: 10.1016/j.jhep.2016.06.027. Epub 2016 Jul 7. Erratum in: J Hepatol. 2017 Jan;66(1):252-253.

23.

Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.

Kowalewski DJ, Walz S, Backert L, Schuster H, Kohlbacher O, Weisel K, Rittig SM, Kanz L, Salih HR, Rammensee HG, Stevanović S, Stickel JS.

Blood Cancer J. 2016 Apr 8;6:e411. doi: 10.1038/bcj.2016.14.

24.

Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanović S, Stickel JS.

Leukemia. 2016 Apr;30(4):1003-4. doi: 10.1038/leu.2016.1. No abstract available.

PMID:
27049048
25.

Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.

Caron E, Kowalewski DJ, Chiek Koh C, Sturm T, Schuster H, Aebersold R.

Mol Cell Proteomics. 2015 Dec;14(12):3105-17. doi: 10.1074/mcp.M115.052431. Review.

26.

An open-source computational and data resource to analyze digital maps of immunopeptidomes.

Caron E, Espona L, Kowalewski DJ, Schuster H, Ternette N, Alpízar A, Schittenhelm RB, Ramarathinam SH, Lindestam Arlehamn CS, Chiek Koh C, Gillet LC, Rabsteyn A, Navarro P, Kim S, Lam H, Sturm T, Marcilla M, Sette A, Campbell DS, Deutsch EW, Moritz RL, Purcell AW, Rammensee HG, Stevanovic S, Aebersold R.

Elife. 2015 Jul 8;4. doi: 10.7554/eLife.07661.

27.

Antileukemia T-cell responses in CLL - We don't need no aberration.

Kowalewski DJ, Stevanovic S, Rammensee HG, Stickel JS.

Oncoimmunology. 2015 Mar 16;4(7):e1011527. eCollection 2015 Jul.

28.

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, Kahn S, Nelde A, Stroh T, Handel M, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Blood. 2015 Sep 3;126(10):1203-13. doi: 10.1182/blood-2015-04-640532. Epub 2015 Jul 2. Erratum in: Blood. 2015 Oct 22;126(17):2072-3.

29.

HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).

Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. doi: 10.1073/pnas.1416389112. Epub 2014 Dec 29. Erratum in: Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6254-6. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6258-60.

30.

Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanović S, Stickel JS.

Leukemia. 2015 Mar;29(3):647-59. doi: 10.1038/leu.2014.233. Epub 2014 Aug 5. Erratum in: Leukemia. 2016 Apr;30(4):1003-4.

PMID:
25092142
31.

A natural tapasin isoform lacking exon 3 modifies peptide loading complex function.

Beutler N, Hauka S, Niepel A, Kowalewski DJ, Uhlmann J, Ghanem E, Erkelenz S, Wiek C, Hanenberg H, Schaal H, Stevanović S, Springer S, Momburg F, Hengel H, Halenius A.

Eur J Immunol. 2013 Jun;43(6):1459-69. doi: 10.1002/eji.201242725. Epub 2013 May 10.

32.

Biochemical large-scale identification of MHC class I ligands.

Kowalewski DJ, Stevanović S.

Methods Mol Biol. 2013;960:145-157. doi: 10.1007/978-1-62703-218-6_12.

PMID:
23329485

Supplemental Content

Loading ...
Support Center